RISE Adult Medication Study

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 267 participants.

Also called NCT01779362

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 267 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01779362
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01779362. Randomized; quadruple masking; primary purpose treatment. Start 2013-04 (registry gives no type); primary completion 2019-02 (actual). Results posted on 2023-05-11.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
RISE Adult Medication Study
Acronym
RISE Adult
Condition
Prediabetes
Intervention (Drug)
Metformin
Intervention (Drug)
Liraglutide
Intervention (Drug)
Glargine
Intervention (Drug)
Placebo
Lead sponsor
RISE Study Group (class: research network)
Collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct01779362
Content hash
a5ea4ed05c395f791f975b5946b2628e88357e67e9afb8e1902b67907c63d3bb